You are here

  • Home
  • Table of contents
  • Table of contents

Table of contents

April 2017 - Volume 2 - 1

A

  1. Ansaloni, Silvia

    1. Impact of intervention aimed at improving the integration of oncology units and local palliative care services: results of the multicentre prospective sequential MIRTO study
      Andrea A Martoni, Barbara Melotti, Claudia Degli Esposti, Vita Mutri, Giorgio Lelli, Silvia Ansaloni, Erico Piva, Elena Strocchi, Franco Pannuti
      ESMO Open Mar 2017, 2 (1) e000116; DOI: 10.1136/esmoopen-2016-000116

  2. Aprile, Giuseppe

    1. Management of metastatic colorectal cancer patients: guidelines of the Italian Medical Oncology Association (AIOM)
      Lisa Salvatore, Giuseppe Aprile, Ermenegildo Arnoldi, Carlo Aschele, Carlo Carnaghi, Maurizio Cosimelli, Evaristo Maiello, Nicola Normanno, Stefania Sciallero, Francesca Valvo, Giordano D Beretta
      ESMO Open Apr 2017, 2 (1) e000147; DOI: 10.1136/esmoopen-2016-000147

  3. Arnoldi, Ermenegildo

    1. Management of metastatic colorectal cancer patients: guidelines of the Italian Medical Oncology Association (AIOM)
      Lisa Salvatore, Giuseppe Aprile, Ermenegildo Arnoldi, Carlo Aschele, Carlo Carnaghi, Maurizio Cosimelli, Evaristo Maiello, Nicola Normanno, Stefania Sciallero, Francesca Valvo, Giordano D Beretta
      ESMO Open Apr 2017, 2 (1) e000147; DOI: 10.1136/esmoopen-2016-000147

  4. Aschele, Carlo

    1. Management of metastatic colorectal cancer patients: guidelines of the Italian Medical Oncology Association (AIOM)
      Lisa Salvatore, Giuseppe Aprile, Ermenegildo Arnoldi, Carlo Aschele, Carlo Carnaghi, Maurizio Cosimelli, Evaristo Maiello, Nicola Normanno, Stefania Sciallero, Francesca Valvo, Giordano D Beretta
      ESMO Open Apr 2017, 2 (1) e000147; DOI: 10.1136/esmoopen-2016-000147

  5. Azambuja, Evandro de

    1. Male breast cancer: finding the way in this uncommon path
      Christian Maurer, Samuel Martel, Evandro de Azambuja
      ESMO Open Mar 2017, 2 (1) e000169; DOI: 10.1136/esmoopen-2017-000169

B

  1. Baba, Hideo

    1. S-1 and oxaliplatin (SOX) plus bevacizumab versus mFOLFOX6 plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer: updated overall survival analyses of the open-label, non-inferiority, randomised phase III: SOFT study
      Hideo Baba, Yasuhide Yamada, Daisuke Takahari, Hiroshi Matsumoto, Kazuhiro Yoshida, Masato Nakamura, Motoki Yoshida, Shigeyoshi Iwamoto, Ken Shimada, Yoshito Komatsu, Yasutsuna Sasaki, Taroh Satoh, Keiichi Takahashi, Hideyuki Mishima, Kei Muro, Masahiko Watanabe, Yuh Sakata, Satoshi Morita, Yasuhiro Shimada, Kenichi Sugihara
      ESMO Open Mar 2017, 2 (1) e000135; DOI: 10.1136/esmoopen-2016-000135

  2. Banerjee, Susana

    1. Indolent peritoneal mesothelioma: PI3K-mTOR inhibitors as a novel therapeutic strategy
      Saoirse O Dolly, Cristina Migali, Nina Tunariu, Chiara Della-Pepa, Shelize Khakoo, Steve Hazell, Johann S de Bono, Stanley B Kaye, Susana Banerjee
      ESMO Open Apr 2017, 2 (1) e000101; DOI: 10.1136/esmoopen-2016-000101

  3. Barrueco, José

    1. Time since start of first-line therapy as a predictive clinical marker for nintedanib in patients with previously treated non-small cell lung cancer
      Birgit Gaschler-Markefski, Patricia Sikken, John V Heymach, Maya Gottfried, Anders Mellemgaard, Silvia Novello, Claudia-Nanette Gann, José Barrueco, Martin Reck, Nasser H Hanna, Rolf Kaiser
      ESMO Open Apr 2017, 2 (1) e000102; DOI: 10.1136/esmoopen-2016-000102

  4. Beretta, Giordano D

    1. Management of metastatic colorectal cancer patients: guidelines of the Italian Medical Oncology Association (AIOM)
      Lisa Salvatore, Giuseppe Aprile, Ermenegildo Arnoldi, Carlo Aschele, Carlo Carnaghi, Maurizio Cosimelli, Evaristo Maiello, Nicola Normanno, Stefania Sciallero, Francesca Valvo, Giordano D Beretta
      ESMO Open Apr 2017, 2 (1) e000147; DOI: 10.1136/esmoopen-2016-000147

  5. Bhattacharjee, Atanu

    1. Phase III study of gefitinib or pemetrexed with carboplatin in EGFR-mutated advanced lung adenocarcinoma
      Vijay Maruti Patil, Vanita Noronha, Amit Joshi, Anuradha Bharat Choughule, Atanu Bhattacharjee, Rajiv Kumar, Supriya Goud, Sucheta More, Anant Ramaswamy, Ashay Karpe, Nikhil Pande, Arun Chandrasekharan, Alok Goel, Vikas Talreja, Abhishek Mahajan, Amit Janu, Nilendu Purandare, Kumar Prabhash
      ESMO Open Apr 2017, 2 (1) e000168; DOI: 10.1136/esmoopen-2017-000168

  6. Boku, Narikazu

    1. Health-related quality of life in a randomised phase III study of gemcitabine plus S-1, S-1 alone and gemcitabine alone for locally advanced or metastatic pancreatic cancer: GEST study
      Yasuhiro Hagiwara, Yasuo Ohashi, Takuji Okusaka, Hideki Ueno, Tatsuya Ioka, Narikazu Boku, Shinichi Egawa, Takashi Hatori, Junji Furuse, Kazuhiro Mizumoto, Shinichi Ohkawa, Taketo Yamaguchi, Kenji Yamao, Akihiro Funakoshi, Ann-Lii Cheng, Kiyohiro Kihara, Atsushi Sato, Masao Tanaka
      ESMO Open Mar 2017, 2 (1) e000151; DOI: 10.1136/esmoopen-2016-000151

C

  1. Caglevic, Christian

    1. Immune checkpoint inhibitors in lung cancer: the holy grail has not yet been found…
      Satheesh Thungappa, Jose Ferri, Christian Caglevic, Francesco Passiglia, Luis Raez, Christian Rolfo
      ESMO Open Mar 2017, 2 (1) e000162; DOI: 10.1136/esmoopen-2017-000162

  2. Carnaghi, Carlo

    1. Management of metastatic colorectal cancer patients: guidelines of the Italian Medical Oncology Association (AIOM)
      Lisa Salvatore, Giuseppe Aprile, Ermenegildo Arnoldi, Carlo Aschele, Carlo Carnaghi, Maurizio Cosimelli, Evaristo Maiello, Nicola Normanno, Stefania Sciallero, Francesca Valvo, Giordano D Beretta
      ESMO Open Apr 2017, 2 (1) e000147; DOI: 10.1136/esmoopen-2016-000147

  3. Cervantes, Andrés

    1. In the literature: February 2017
      Andrés Cervantes, María José Terol
      ESMO Open Mar 2017, 2 (1) e000171; DOI: 10.1136/esmoopen-2017-000171

  4. Chan, Anthony TC

    1. Biologics and biosimilars: what, why and how?
      Juliana CN Chan, Anthony TC Chan
      ESMO Open Mar 2017, 2 (1) e000180; DOI: 10.1136/esmoopen-2017-000180

  5. Chan, Juliana CN

    1. Biologics and biosimilars: what, why and how?
      Juliana CN Chan, Anthony TC Chan
      ESMO Open Mar 2017, 2 (1) e000180; DOI: 10.1136/esmoopen-2017-000180

  6. Chandrasekharan, Arun

    1. Phase III study of gefitinib or pemetrexed with carboplatin in EGFR-mutated advanced lung adenocarcinoma
      Vijay Maruti Patil, Vanita Noronha, Amit Joshi, Anuradha Bharat Choughule, Atanu Bhattacharjee, Rajiv Kumar, Supriya Goud, Sucheta More, Anant Ramaswamy, Ashay Karpe, Nikhil Pande, Arun Chandrasekharan, Alok Goel, Vikas Talreja, Abhishek Mahajan, Amit Janu, Nilendu Purandare, Kumar Prabhash
      ESMO Open Apr 2017, 2 (1) e000168; DOI: 10.1136/esmoopen-2017-000168

  7. Cheng, Ann-Lii

    1. Health-related quality of life in a randomised phase III study of gemcitabine plus S-1, S-1 alone and gemcitabine alone for locally advanced or metastatic pancreatic cancer: GEST study
      Yasuhiro Hagiwara, Yasuo Ohashi, Takuji Okusaka, Hideki Ueno, Tatsuya Ioka, Narikazu Boku, Shinichi Egawa, Takashi Hatori, Junji Furuse, Kazuhiro Mizumoto, Shinichi Ohkawa, Taketo Yamaguchi, Kenji Yamao, Akihiro Funakoshi, Ann-Lii Cheng, Kiyohiro Kihara, Atsushi Sato, Masao Tanaka
      ESMO Open Mar 2017, 2 (1) e000151; DOI: 10.1136/esmoopen-2016-000151

  8. Chouaki, Nadia

    1. Pemetrexed-cisplatin with concurrent thoracic radiation after pemetrexed-cisplatin induction in patients with unresectable locally advanced non-squamous NSCLC: results by age subgroup
      Pilar Garrido, Nadia Chouaki, Monika Serke, Philippe Giraud, Umberto Ricardi, Carmen Vallejo, Carla Visseren-Grul, Victoria Soldatenkova, Silvia Novello
      ESMO Open Mar 2017, 2 (1) e000141; DOI: 10.1136/esmoopen-2016-000141

  9. Choughule, Anuradha Bharat

    1. Phase III study of gefitinib or pemetrexed with carboplatin in EGFR-mutated advanced lung adenocarcinoma
      Vijay Maruti Patil, Vanita Noronha, Amit Joshi, Anuradha Bharat Choughule, Atanu Bhattacharjee, Rajiv Kumar, Supriya Goud, Sucheta More, Anant Ramaswamy, Ashay Karpe, Nikhil Pande, Arun Chandrasekharan, Alok Goel, Vikas Talreja, Abhishek Mahajan, Amit Janu, Nilendu Purandare, Kumar Prabhash
      ESMO Open Apr 2017, 2 (1) e000168; DOI: 10.1136/esmoopen-2017-000168

  10. Cosimelli, Maurizio

    1. Management of metastatic colorectal cancer patients: guidelines of the Italian Medical Oncology Association (AIOM)
      Lisa Salvatore, Giuseppe Aprile, Ermenegildo Arnoldi, Carlo Aschele, Carlo Carnaghi, Maurizio Cosimelli, Evaristo Maiello, Nicola Normanno, Stefania Sciallero, Francesca Valvo, Giordano D Beretta
      ESMO Open Apr 2017, 2 (1) e000147; DOI: 10.1136/esmoopen-2016-000147

D

  1. Degli Esposti, Claudia

    1. Impact of intervention aimed at improving the integration of oncology units and local palliative care services: results of the multicentre prospective sequential MIRTO study
      Andrea A Martoni, Barbara Melotti, Claudia Degli Esposti, Vita Mutri, Giorgio Lelli, Silvia Ansaloni, Erico Piva, Elena Strocchi, Franco Pannuti
      ESMO Open Mar 2017, 2 (1) e000116; DOI: 10.1136/esmoopen-2016-000116

  2. Della-Pepa, Chiara

    1. Indolent peritoneal mesothelioma: PI3K-mTOR inhibitors as a novel therapeutic strategy
      Saoirse O Dolly, Cristina Migali, Nina Tunariu, Chiara Della-Pepa, Shelize Khakoo, Steve Hazell, Johann S de Bono, Stanley B Kaye, Susana Banerjee
      ESMO Open Apr 2017, 2 (1) e000101; DOI: 10.1136/esmoopen-2016-000101

  3. Dolly, Saoirse O

    1. Indolent peritoneal mesothelioma: PI3K-mTOR inhibitors as a novel therapeutic strategy
      Saoirse O Dolly, Cristina Migali, Nina Tunariu, Chiara Della-Pepa, Shelize Khakoo, Steve Hazell, Johann S de Bono, Stanley B Kaye, Susana Banerjee
      ESMO Open Apr 2017, 2 (1) e000101; DOI: 10.1136/esmoopen-2016-000101

E

  1. Egawa, Shinichi

    1. Health-related quality of life in a randomised phase III study of gemcitabine plus S-1, S-1 alone and gemcitabine alone for locally advanced or metastatic pancreatic cancer: GEST study
      Yasuhiro Hagiwara, Yasuo Ohashi, Takuji Okusaka, Hideki Ueno, Tatsuya Ioka, Narikazu Boku, Shinichi Egawa, Takashi Hatori, Junji Furuse, Kazuhiro Mizumoto, Shinichi Ohkawa, Taketo Yamaguchi, Kenji Yamao, Akihiro Funakoshi, Ann-Lii Cheng, Kiyohiro Kihara, Atsushi Sato, Masao Tanaka
      ESMO Open Mar 2017, 2 (1) e000151; DOI: 10.1136/esmoopen-2016-000151

F

  1. Ferri, Jose

    1. Immune checkpoint inhibitors in lung cancer: the holy grail has not yet been found…
      Satheesh Thungappa, Jose Ferri, Christian Caglevic, Francesco Passiglia, Luis Raez, Christian Rolfo
      ESMO Open Mar 2017, 2 (1) e000162; DOI: 10.1136/esmoopen-2017-000162

  2. Funakoshi, Akihiro

    1. Health-related quality of life in a randomised phase III study of gemcitabine plus S-1, S-1 alone and gemcitabine alone for locally advanced or metastatic pancreatic cancer: GEST study
      Yasuhiro Hagiwara, Yasuo Ohashi, Takuji Okusaka, Hideki Ueno, Tatsuya Ioka, Narikazu Boku, Shinichi Egawa, Takashi Hatori, Junji Furuse, Kazuhiro Mizumoto, Shinichi Ohkawa, Taketo Yamaguchi, Kenji Yamao, Akihiro Funakoshi, Ann-Lii Cheng, Kiyohiro Kihara, Atsushi Sato, Masao Tanaka
      ESMO Open Mar 2017, 2 (1) e000151; DOI: 10.1136/esmoopen-2016-000151

  3. Furuse, Junji

    1. Health-related quality of life in a randomised phase III study of gemcitabine plus S-1, S-1 alone and gemcitabine alone for locally advanced or metastatic pancreatic cancer: GEST study
      Yasuhiro Hagiwara, Yasuo Ohashi, Takuji Okusaka, Hideki Ueno, Tatsuya Ioka, Narikazu Boku, Shinichi Egawa, Takashi Hatori, Junji Furuse, Kazuhiro Mizumoto, Shinichi Ohkawa, Taketo Yamaguchi, Kenji Yamao, Akihiro Funakoshi, Ann-Lii Cheng, Kiyohiro Kihara, Atsushi Sato, Masao Tanaka
      ESMO Open Mar 2017, 2 (1) e000151; DOI: 10.1136/esmoopen-2016-000151

G

  1. Gann, Claudia-Nanette

    1. Time since start of first-line therapy as a predictive clinical marker for nintedanib in patients with previously treated non-small cell lung cancer
      Birgit Gaschler-Markefski, Patricia Sikken, John V Heymach, Maya Gottfried, Anders Mellemgaard, Silvia Novello, Claudia-Nanette Gann, José Barrueco, Martin Reck, Nasser H Hanna, Rolf Kaiser
      ESMO Open Apr 2017, 2 (1) e000102; DOI: 10.1136/esmoopen-2016-000102

  2. Garrido, Pilar

    1. Pemetrexed-cisplatin with concurrent thoracic radiation after pemetrexed-cisplatin induction in patients with unresectable locally advanced non-squamous NSCLC: results by age subgroup
      Pilar Garrido, Nadia Chouaki, Monika Serke, Philippe Giraud, Umberto Ricardi, Carmen Vallejo, Carla Visseren-Grul, Victoria Soldatenkova, Silvia Novello
      ESMO Open Mar 2017, 2 (1) e000141; DOI: 10.1136/esmoopen-2016-000141

  3. Gaschler-Markefski, Birgit

    1. Time since start of first-line therapy as a predictive clinical marker for nintedanib in patients with previously treated non-small cell lung cancer
      Birgit Gaschler-Markefski, Patricia Sikken, John V Heymach, Maya Gottfried, Anders Mellemgaard, Silvia Novello, Claudia-Nanette Gann, José Barrueco, Martin Reck, Nasser H Hanna, Rolf Kaiser
      ESMO Open Apr 2017, 2 (1) e000102; DOI: 10.1136/esmoopen-2016-000102

  4. Giraud, Philippe

    1. Pemetrexed-cisplatin with concurrent thoracic radiation after pemetrexed-cisplatin induction in patients with unresectable locally advanced non-squamous NSCLC: results by age subgroup
      Pilar Garrido, Nadia Chouaki, Monika Serke, Philippe Giraud, Umberto Ricardi, Carmen Vallejo, Carla Visseren-Grul, Victoria Soldatenkova, Silvia Novello
      ESMO Open Mar 2017, 2 (1) e000141; DOI: 10.1136/esmoopen-2016-000141

  5. Goel, Alok

    1. Phase III study of gefitinib or pemetrexed with carboplatin in EGFR-mutated advanced lung adenocarcinoma
      Vijay Maruti Patil, Vanita Noronha, Amit Joshi, Anuradha Bharat Choughule, Atanu Bhattacharjee, Rajiv Kumar, Supriya Goud, Sucheta More, Anant Ramaswamy, Ashay Karpe, Nikhil Pande, Arun Chandrasekharan, Alok Goel, Vikas Talreja, Abhishek Mahajan, Amit Janu, Nilendu Purandare, Kumar Prabhash
      ESMO Open Apr 2017, 2 (1) e000168; DOI: 10.1136/esmoopen-2017-000168

  6. Gottfried, Maya

    1. Time since start of first-line therapy as a predictive clinical marker for nintedanib in patients with previously treated non-small cell lung cancer
      Birgit Gaschler-Markefski, Patricia Sikken, John V Heymach, Maya Gottfried, Anders Mellemgaard, Silvia Novello, Claudia-Nanette Gann, José Barrueco, Martin Reck, Nasser H Hanna, Rolf Kaiser
      ESMO Open Apr 2017, 2 (1) e000102; DOI: 10.1136/esmoopen-2016-000102

  7. Goud, Supriya

    1. Phase III study of gefitinib or pemetrexed with carboplatin in EGFR-mutated advanced lung adenocarcinoma
      Vijay Maruti Patil, Vanita Noronha, Amit Joshi, Anuradha Bharat Choughule, Atanu Bhattacharjee, Rajiv Kumar, Supriya Goud, Sucheta More, Anant Ramaswamy, Ashay Karpe, Nikhil Pande, Arun Chandrasekharan, Alok Goel, Vikas Talreja, Abhishek Mahajan, Amit Janu, Nilendu Purandare, Kumar Prabhash
      ESMO Open Apr 2017, 2 (1) e000168; DOI: 10.1136/esmoopen-2017-000168

H

  1. Hagiwara, Yasuhiro

    1. Health-related quality of life in a randomised phase III study of gemcitabine plus S-1, S-1 alone and gemcitabine alone for locally advanced or metastatic pancreatic cancer: GEST study
      Yasuhiro Hagiwara, Yasuo Ohashi, Takuji Okusaka, Hideki Ueno, Tatsuya Ioka, Narikazu Boku, Shinichi Egawa, Takashi Hatori, Junji Furuse, Kazuhiro Mizumoto, Shinichi Ohkawa, Taketo Yamaguchi, Kenji Yamao, Akihiro Funakoshi, Ann-Lii Cheng, Kiyohiro Kihara, Atsushi Sato, Masao Tanaka
      ESMO Open Mar 2017, 2 (1) e000151; DOI: 10.1136/esmoopen-2016-000151

  2. Hanna, Nasser H

    1. Time since start of first-line therapy as a predictive clinical marker for nintedanib in patients with previously treated non-small cell lung cancer
      Birgit Gaschler-Markefski, Patricia Sikken, John V Heymach, Maya Gottfried, Anders Mellemgaard, Silvia Novello, Claudia-Nanette Gann, José Barrueco, Martin Reck, Nasser H Hanna, Rolf Kaiser
      ESMO Open Apr 2017, 2 (1) e000102; DOI: 10.1136/esmoopen-2016-000102

  3. Hashida, Hiroki

    1. Phase I study of neoadjuvant chemotherapy with S-1 and oxaliplatin for locally advanced gastric cancer (Neo G-SOX PI)
      Hironaga Satake, Akira Miki, Masato Kondo, Takeshi Kotake, Yoshihiro Okita, Yukimasa Hatachi, Hisateru Yasui, Yukihiro Imai, Chihiro Ichikawa, Kenta Murotani, Hiroki Hashida, Hiroyuki Kobayashi, Masahito Kotaka, Takeshi Kato, Satoshi Kaihara, Akihito Tsuji
      ESMO Open Mar 2017, 2 (1) e000130; DOI: 10.1136/esmoopen-2016-000130

  4. Hashimoto, Kazuki

    1. Prevalence of hypothyroidism among patients with breast cancer treated with radiation to the supraclavicular field: a single-centre survey
      Yuichiro Kikawa, Yasuhiro Kosaka, Kazuki Hashimoto, Eri Hohokabe, Sayaka Takebe, Ryo Narukami, Takayuki Hattori, Kazuhiro Ueki, Kengo Ogura, Toshiyuki Imagumbai, Hironori Kato, Masaki Kokubo
      ESMO Open Apr 2017, 2 (1) e000161; DOI: 10.1136/esmoopen-2017-000161

  5. Hatachi, Yukimasa

    1. Phase I study of neoadjuvant chemotherapy with S-1 and oxaliplatin for locally advanced gastric cancer (Neo G-SOX PI)
      Hironaga Satake, Akira Miki, Masato Kondo, Takeshi Kotake, Yoshihiro Okita, Yukimasa Hatachi, Hisateru Yasui, Yukihiro Imai, Chihiro Ichikawa, Kenta Murotani, Hiroki Hashida, Hiroyuki Kobayashi, Masahito Kotaka, Takeshi Kato, Satoshi Kaihara, Akihito Tsuji
      ESMO Open Mar 2017, 2 (1) e000130; DOI: 10.1136/esmoopen-2016-000130

  6. Hatori, Takashi

    1. Health-related quality of life in a randomised phase III study of gemcitabine plus S-1, S-1 alone and gemcitabine alone for locally advanced or metastatic pancreatic cancer: GEST study
      Yasuhiro Hagiwara, Yasuo Ohashi, Takuji Okusaka, Hideki Ueno, Tatsuya Ioka, Narikazu Boku, Shinichi Egawa, Takashi Hatori, Junji Furuse, Kazuhiro Mizumoto, Shinichi Ohkawa, Taketo Yamaguchi, Kenji Yamao, Akihiro Funakoshi, Ann-Lii Cheng, Kiyohiro Kihara, Atsushi Sato, Masao Tanaka
      ESMO Open Mar 2017, 2 (1) e000151; DOI: 10.1136/esmoopen-2016-000151

  7. Hattori, Takayuki

    1. Prevalence of hypothyroidism among patients with breast cancer treated with radiation to the supraclavicular field: a single-centre survey
      Yuichiro Kikawa, Yasuhiro Kosaka, Kazuki Hashimoto, Eri Hohokabe, Sayaka Takebe, Ryo Narukami, Takayuki Hattori, Kazuhiro Ueki, Kengo Ogura, Toshiyuki Imagumbai, Hironori Kato, Masaki Kokubo
      ESMO Open Apr 2017, 2 (1) e000161; DOI: 10.1136/esmoopen-2017-000161

  8. Hayashi, Hidetoshi

    1. Peritumoural ground-glass opacity associated with tumour pseudoprogression in a patient with non-small cell lung cancer treated with nivolumab
      Ryoji Kato, Hidetoshi Hayashi, Junko Tanizaki, Kaoru Tanaka, Masayuki Takeda, Kazuhiko Nakagawa
      ESMO Open Mar 2017, 2 (1) e000145; DOI: 10.1136/esmoopen-2016-000145

  9. Hazell, Steve

    1. Indolent peritoneal mesothelioma: PI3K-mTOR inhibitors as a novel therapeutic strategy
      Saoirse O Dolly, Cristina Migali, Nina Tunariu, Chiara Della-Pepa, Shelize Khakoo, Steve Hazell, Johann S de Bono, Stanley B Kaye, Susana Banerjee
      ESMO Open Apr 2017, 2 (1) e000101; DOI: 10.1136/esmoopen-2016-000101

  10. Heymach, John V

    1. Time since start of first-line therapy as a predictive clinical marker for nintedanib in patients with previously treated non-small cell lung cancer
      Birgit Gaschler-Markefski, Patricia Sikken, John V Heymach, Maya Gottfried, Anders Mellemgaard, Silvia Novello, Claudia-Nanette Gann, José Barrueco, Martin Reck, Nasser H Hanna, Rolf Kaiser
      ESMO Open Apr 2017, 2 (1) e000102; DOI: 10.1136/esmoopen-2016-000102

  11. Hohokabe, Eri

    1. Prevalence of hypothyroidism among patients with breast cancer treated with radiation to the supraclavicular field: a single-centre survey
      Yuichiro Kikawa, Yasuhiro Kosaka, Kazuki Hashimoto, Eri Hohokabe, Sayaka Takebe, Ryo Narukami, Takayuki Hattori, Kazuhiro Ueki, Kengo Ogura, Toshiyuki Imagumbai, Hironori Kato, Masaki Kokubo
      ESMO Open Apr 2017, 2 (1) e000161; DOI: 10.1136/esmoopen-2017-000161

I

  1. Ichikawa, Chihiro

    1. Phase I study of neoadjuvant chemotherapy with S-1 and oxaliplatin for locally advanced gastric cancer (Neo G-SOX PI)
      Hironaga Satake, Akira Miki, Masato Kondo, Takeshi Kotake, Yoshihiro Okita, Yukimasa Hatachi, Hisateru Yasui, Yukihiro Imai, Chihiro Ichikawa, Kenta Murotani, Hiroki Hashida, Hiroyuki Kobayashi, Masahito Kotaka, Takeshi Kato, Satoshi Kaihara, Akihito Tsuji
      ESMO Open Mar 2017, 2 (1) e000130; DOI: 10.1136/esmoopen-2016-000130

  2. Imagumbai, Toshiyuki

    1. Prevalence of hypothyroidism among patients with breast cancer treated with radiation to the supraclavicular field: a single-centre survey
      Yuichiro Kikawa, Yasuhiro Kosaka, Kazuki Hashimoto, Eri Hohokabe, Sayaka Takebe, Ryo Narukami, Takayuki Hattori, Kazuhiro Ueki, Kengo Ogura, Toshiyuki Imagumbai, Hironori Kato, Masaki Kokubo
      ESMO Open Apr 2017, 2 (1) e000161; DOI: 10.1136/esmoopen-2017-000161

  3. Imai, Yukihiro

    1. Phase I study of neoadjuvant chemotherapy with S-1 and oxaliplatin for locally advanced gastric cancer (Neo G-SOX PI)
      Hironaga Satake, Akira Miki, Masato Kondo, Takeshi Kotake, Yoshihiro Okita, Yukimasa Hatachi, Hisateru Yasui, Yukihiro Imai, Chihiro Ichikawa, Kenta Murotani, Hiroki Hashida, Hiroyuki Kobayashi, Masahito Kotaka, Takeshi Kato, Satoshi Kaihara, Akihito Tsuji
      ESMO Open Mar 2017, 2 (1) e000130; DOI: 10.1136/esmoopen-2016-000130

  4. Ioka, Tatsuya

    1. Health-related quality of life in a randomised phase III study of gemcitabine plus S-1, S-1 alone and gemcitabine alone for locally advanced or metastatic pancreatic cancer: GEST study
      Yasuhiro Hagiwara, Yasuo Ohashi, Takuji Okusaka, Hideki Ueno, Tatsuya Ioka, Narikazu Boku, Shinichi Egawa, Takashi Hatori, Junji Furuse, Kazuhiro Mizumoto, Shinichi Ohkawa, Taketo Yamaguchi, Kenji Yamao, Akihiro Funakoshi, Ann-Lii Cheng, Kiyohiro Kihara, Atsushi Sato, Masao Tanaka
      ESMO Open Mar 2017, 2 (1) e000151; DOI: 10.1136/esmoopen-2016-000151

  5. Iwamoto, Shigeyoshi

    1. S-1 and oxaliplatin (SOX) plus bevacizumab versus mFOLFOX6 plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer: updated overall survival analyses of the open-label, non-inferiority, randomised phase III: SOFT study
      Hideo Baba, Yasuhide Yamada, Daisuke Takahari, Hiroshi Matsumoto, Kazuhiro Yoshida, Masato Nakamura, Motoki Yoshida, Shigeyoshi Iwamoto, Ken Shimada, Yoshito Komatsu, Yasutsuna Sasaki, Taroh Satoh, Keiichi Takahashi, Hideyuki Mishima, Kei Muro, Masahiko Watanabe, Yuh Sakata, Satoshi Morita, Yasuhiro Shimada, Kenichi Sugihara
      ESMO Open Mar 2017, 2 (1) e000135; DOI: 10.1136/esmoopen-2016-000135

J

  1. Janu, Amit

    1. Phase III study of gefitinib or pemetrexed with carboplatin in EGFR-mutated advanced lung adenocarcinoma
      Vijay Maruti Patil, Vanita Noronha, Amit Joshi, Anuradha Bharat Choughule, Atanu Bhattacharjee, Rajiv Kumar, Supriya Goud, Sucheta More, Anant Ramaswamy, Ashay Karpe, Nikhil Pande, Arun Chandrasekharan, Alok Goel, Vikas Talreja, Abhishek Mahajan, Amit Janu, Nilendu Purandare, Kumar Prabhash
      ESMO Open Apr 2017, 2 (1) e000168; DOI: 10.1136/esmoopen-2017-000168

  2. Joshi, Amit

    1. Phase III study of gefitinib or pemetrexed with carboplatin in EGFR-mutated advanced lung adenocarcinoma
      Vijay Maruti Patil, Vanita Noronha, Amit Joshi, Anuradha Bharat Choughule, Atanu Bhattacharjee, Rajiv Kumar, Supriya Goud, Sucheta More, Anant Ramaswamy, Ashay Karpe, Nikhil Pande, Arun Chandrasekharan, Alok Goel, Vikas Talreja, Abhishek Mahajan, Amit Janu, Nilendu Purandare, Kumar Prabhash
      ESMO Open Apr 2017, 2 (1) e000168; DOI: 10.1136/esmoopen-2017-000168

K

  1. Kaihara, Satoshi

    1. Phase I study of neoadjuvant chemotherapy with S-1 and oxaliplatin for locally advanced gastric cancer (Neo G-SOX PI)
      Hironaga Satake, Akira Miki, Masato Kondo, Takeshi Kotake, Yoshihiro Okita, Yukimasa Hatachi, Hisateru Yasui, Yukihiro Imai, Chihiro Ichikawa, Kenta Murotani, Hiroki Hashida, Hiroyuki Kobayashi, Masahito Kotaka, Takeshi Kato, Satoshi Kaihara, Akihito Tsuji
      ESMO Open Mar 2017, 2 (1) e000130; DOI: 10.1136/esmoopen-2016-000130

  2. Kaiser, Rolf

    1. Time since start of first-line therapy as a predictive clinical marker for nintedanib in patients with previously treated non-small cell lung cancer
      Birgit Gaschler-Markefski, Patricia Sikken, John V Heymach, Maya Gottfried, Anders Mellemgaard, Silvia Novello, Claudia-Nanette Gann, José Barrueco, Martin Reck, Nasser H Hanna, Rolf Kaiser
      ESMO Open Apr 2017, 2 (1) e000102; DOI: 10.1136/esmoopen-2016-000102

  3. Karpe, Ashay

    1. Phase III study of gefitinib or pemetrexed with carboplatin in EGFR-mutated advanced lung adenocarcinoma
      Vijay Maruti Patil, Vanita Noronha, Amit Joshi, Anuradha Bharat Choughule, Atanu Bhattacharjee, Rajiv Kumar, Supriya Goud, Sucheta More, Anant Ramaswamy, Ashay Karpe, Nikhil Pande, Arun Chandrasekharan, Alok Goel, Vikas Talreja, Abhishek Mahajan, Amit Janu, Nilendu Purandare, Kumar Prabhash
      ESMO Open Apr 2017, 2 (1) e000168; DOI: 10.1136/esmoopen-2017-000168

  4. Kato, Hironori

    1. Prevalence of hypothyroidism among patients with breast cancer treated with radiation to the supraclavicular field: a single-centre survey
      Yuichiro Kikawa, Yasuhiro Kosaka, Kazuki Hashimoto, Eri Hohokabe, Sayaka Takebe, Ryo Narukami, Takayuki Hattori, Kazuhiro Ueki, Kengo Ogura, Toshiyuki Imagumbai, Hironori Kato, Masaki Kokubo
      ESMO Open Apr 2017, 2 (1) e000161; DOI: 10.1136/esmoopen-2017-000161

  5. Kato, Ryoji

    1. Peritumoural ground-glass opacity associated with tumour pseudoprogression in a patient with non-small cell lung cancer treated with nivolumab
      Ryoji Kato, Hidetoshi Hayashi, Junko Tanizaki, Kaoru Tanaka, Masayuki Takeda, Kazuhiko Nakagawa
      ESMO Open Mar 2017, 2 (1) e000145; DOI: 10.1136/esmoopen-2016-000145

  6. Kato, Takeshi

    1. Phase I study of neoadjuvant chemotherapy with S-1 and oxaliplatin for locally advanced gastric cancer (Neo G-SOX PI)
      Hironaga Satake, Akira Miki, Masato Kondo, Takeshi Kotake, Yoshihiro Okita, Yukimasa Hatachi, Hisateru Yasui, Yukihiro Imai, Chihiro Ichikawa, Kenta Murotani, Hiroki Hashida, Hiroyuki Kobayashi, Masahito Kotaka, Takeshi Kato, Satoshi Kaihara, Akihito Tsuji
      ESMO Open Mar 2017, 2 (1) e000130; DOI: 10.1136/esmoopen-2016-000130

  7. Kaye, Stanley B

    1. Indolent peritoneal mesothelioma: PI3K-mTOR inhibitors as a novel therapeutic strategy
      Saoirse O Dolly, Cristina Migali, Nina Tunariu, Chiara Della-Pepa, Shelize Khakoo, Steve Hazell, Johann S de Bono, Stanley B Kaye, Susana Banerjee
      ESMO Open Apr 2017, 2 (1) e000101; DOI: 10.1136/esmoopen-2016-000101

  8. Khakoo, Shelize

    1. Indolent peritoneal mesothelioma: PI3K-mTOR inhibitors as a novel therapeutic strategy
      Saoirse O Dolly, Cristina Migali, Nina Tunariu, Chiara Della-Pepa, Shelize Khakoo, Steve Hazell, Johann S de Bono, Stanley B Kaye, Susana Banerjee
      ESMO Open Apr 2017, 2 (1) e000101; DOI: 10.1136/esmoopen-2016-000101

  9. Kihara, Kiyohiro

    1. Health-related quality of life in a randomised phase III study of gemcitabine plus S-1, S-1 alone and gemcitabine alone for locally advanced or metastatic pancreatic cancer: GEST study
      Yasuhiro Hagiwara, Yasuo Ohashi, Takuji Okusaka, Hideki Ueno, Tatsuya Ioka, Narikazu Boku, Shinichi Egawa, Takashi Hatori, Junji Furuse, Kazuhiro Mizumoto, Shinichi Ohkawa, Taketo Yamaguchi, Kenji Yamao, Akihiro Funakoshi, Ann-Lii Cheng, Kiyohiro Kihara, Atsushi Sato, Masao Tanaka
      ESMO Open Mar 2017, 2 (1) e000151; DOI: 10.1136/esmoopen-2016-000151

  10. Kikawa, Yuichiro

    1. Prevalence of hypothyroidism among patients with breast cancer treated with radiation to the supraclavicular field: a single-centre survey
      Yuichiro Kikawa, Yasuhiro Kosaka, Kazuki Hashimoto, Eri Hohokabe, Sayaka Takebe, Ryo Narukami, Takayuki Hattori, Kazuhiro Ueki, Kengo Ogura, Toshiyuki Imagumbai, Hironori Kato, Masaki Kokubo
      ESMO Open Apr 2017, 2 (1) e000161; DOI: 10.1136/esmoopen-2017-000161

  11. Kobayashi, Hiroyuki

    1. Phase I study of neoadjuvant chemotherapy with S-1 and oxaliplatin for locally advanced gastric cancer (Neo G-SOX PI)
      Hironaga Satake, Akira Miki, Masato Kondo, Takeshi Kotake, Yoshihiro Okita, Yukimasa Hatachi, Hisateru Yasui, Yukihiro Imai, Chihiro Ichikawa, Kenta Murotani, Hiroki Hashida, Hiroyuki Kobayashi, Masahito Kotaka, Takeshi Kato, Satoshi Kaihara, Akihito Tsuji
      ESMO Open Mar 2017, 2 (1) e000130; DOI: 10.1136/esmoopen-2016-000130

  12. Kokubo, Masaki

    1. Prevalence of hypothyroidism among patients with breast cancer treated with radiation to the supraclavicular field: a single-centre survey
      Yuichiro Kikawa, Yasuhiro Kosaka, Kazuki Hashimoto, Eri Hohokabe, Sayaka Takebe, Ryo Narukami, Takayuki Hattori, Kazuhiro Ueki, Kengo Ogura, Toshiyuki Imagumbai, Hironori Kato, Masaki Kokubo
      ESMO Open Apr 2017, 2 (1) e000161; DOI: 10.1136/esmoopen-2017-000161

  13. Komatsu, Yoshito

    1. S-1 and oxaliplatin (SOX) plus bevacizumab versus mFOLFOX6 plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer: updated overall survival analyses of the open-label, non-inferiority, randomised phase III: SOFT study
      Hideo Baba, Yasuhide Yamada, Daisuke Takahari, Hiroshi Matsumoto, Kazuhiro Yoshida, Masato Nakamura, Motoki Yoshida, Shigeyoshi Iwamoto, Ken Shimada, Yoshito Komatsu, Yasutsuna Sasaki, Taroh Satoh, Keiichi Takahashi, Hideyuki Mishima, Kei Muro, Masahiko Watanabe, Yuh Sakata, Satoshi Morita, Yasuhiro Shimada, Kenichi Sugihara
      ESMO Open Mar 2017, 2 (1) e000135; DOI: 10.1136/esmoopen-2016-000135

  14. Kondo, Masato

    1. Phase I study of neoadjuvant chemotherapy with S-1 and oxaliplatin for locally advanced gastric cancer (Neo G-SOX PI)
      Hironaga Satake, Akira Miki, Masato Kondo, Takeshi Kotake, Yoshihiro Okita, Yukimasa Hatachi, Hisateru Yasui, Yukihiro Imai, Chihiro Ichikawa, Kenta Murotani, Hiroki Hashida, Hiroyuki Kobayashi, Masahito Kotaka, Takeshi Kato, Satoshi Kaihara, Akihito Tsuji
      ESMO Open Mar 2017, 2 (1) e000130; DOI: 10.1136/esmoopen-2016-000130

  15. Kosaka, Yasuhiro

    1. Prevalence of hypothyroidism among patients with breast cancer treated with radiation to the supraclavicular field: a single-centre survey
      Yuichiro Kikawa, Yasuhiro Kosaka, Kazuki Hashimoto, Eri Hohokabe, Sayaka Takebe, Ryo Narukami, Takayuki Hattori, Kazuhiro Ueki, Kengo Ogura, Toshiyuki Imagumbai, Hironori Kato, Masaki Kokubo
      ESMO Open Apr 2017, 2 (1) e000161; DOI: 10.1136/esmoopen-2017-000161

  16. Kotaka, Masahito

    1. Phase I study of neoadjuvant chemotherapy with S-1 and oxaliplatin for locally advanced gastric cancer (Neo G-SOX PI)
      Hironaga Satake, Akira Miki, Masato Kondo, Takeshi Kotake, Yoshihiro Okita, Yukimasa Hatachi, Hisateru Yasui, Yukihiro Imai, Chihiro Ichikawa, Kenta Murotani, Hiroki Hashida, Hiroyuki Kobayashi, Masahito Kotaka, Takeshi Kato, Satoshi Kaihara, Akihito Tsuji
      ESMO Open Mar 2017, 2 (1) e000130; DOI: 10.1136/esmoopen-2016-000130

  17. Kotake, Takeshi

    1. Phase I study of neoadjuvant chemotherapy with S-1 and oxaliplatin for locally advanced gastric cancer (Neo G-SOX PI)
      Hironaga Satake, Akira Miki, Masato Kondo, Takeshi Kotake, Yoshihiro Okita, Yukimasa Hatachi, Hisateru Yasui, Yukihiro Imai, Chihiro Ichikawa, Kenta Murotani, Hiroki Hashida, Hiroyuki Kobayashi, Masahito Kotaka, Takeshi Kato, Satoshi Kaihara, Akihito Tsuji
      ESMO Open Mar 2017, 2 (1) e000130; DOI: 10.1136/esmoopen-2016-000130

  18. Kumar, Rajiv

    1. Phase III study of gefitinib or pemetrexed with carboplatin in EGFR-mutated advanced lung adenocarcinoma
      Vijay Maruti Patil, Vanita Noronha, Amit Joshi, Anuradha Bharat Choughule, Atanu Bhattacharjee, Rajiv Kumar, Supriya Goud, Sucheta More, Anant Ramaswamy, Ashay Karpe, Nikhil Pande, Arun Chandrasekharan, Alok Goel, Vikas Talreja, Abhishek Mahajan, Amit Janu, Nilendu Purandare, Kumar Prabhash
      ESMO Open Apr 2017, 2 (1) e000168; DOI: 10.1136/esmoopen-2017-000168

L

  1. Lelli, Giorgio

    1. Impact of intervention aimed at improving the integration of oncology units and local palliative care services: results of the multicentre prospective sequential MIRTO study
      Andrea A Martoni, Barbara Melotti, Claudia Degli Esposti, Vita Mutri, Giorgio Lelli, Silvia Ansaloni, Erico Piva, Elena Strocchi, Franco Pannuti
      ESMO Open Mar 2017, 2 (1) e000116; DOI: 10.1136/esmoopen-2016-000116

M

  1. Mahajan, Abhishek

    1. Phase III study of gefitinib or pemetrexed with carboplatin in EGFR-mutated advanced lung adenocarcinoma
      Vijay Maruti Patil, Vanita Noronha, Amit Joshi, Anuradha Bharat Choughule, Atanu Bhattacharjee, Rajiv Kumar, Supriya Goud, Sucheta More, Anant Ramaswamy, Ashay Karpe, Nikhil Pande, Arun Chandrasekharan, Alok Goel, Vikas Talreja, Abhishek Mahajan, Amit Janu, Nilendu Purandare, Kumar Prabhash
      ESMO Open Apr 2017, 2 (1) e000168; DOI: 10.1136/esmoopen-2017-000168

  2. Maiello, Evaristo

    1. Management of metastatic colorectal cancer patients: guidelines of the Italian Medical Oncology Association (AIOM)
      Lisa Salvatore, Giuseppe Aprile, Ermenegildo Arnoldi, Carlo Aschele, Carlo Carnaghi, Maurizio Cosimelli, Evaristo Maiello, Nicola Normanno, Stefania Sciallero, Francesca Valvo, Giordano D Beretta
      ESMO Open Apr 2017, 2 (1) e000147; DOI: 10.1136/esmoopen-2016-000147

  3. Martel, Samuel

    1. Male breast cancer: finding the way in this uncommon path
      Christian Maurer, Samuel Martel, Evandro de Azambuja
      ESMO Open Mar 2017, 2 (1) e000169; DOI: 10.1136/esmoopen-2017-000169

  4. Martoni, Andrea A

    1. Impact of intervention aimed at improving the integration of oncology units and local palliative care services: results of the multicentre prospective sequential MIRTO study
      Andrea A Martoni, Barbara Melotti, Claudia Degli Esposti, Vita Mutri, Giorgio Lelli, Silvia Ansaloni, Erico Piva, Elena Strocchi, Franco Pannuti
      ESMO Open Mar 2017, 2 (1) e000116; DOI: 10.1136/esmoopen-2016-000116

  5. Matsumoto, Hiroshi

    1. S-1 and oxaliplatin (SOX) plus bevacizumab versus mFOLFOX6 plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer: updated overall survival analyses of the open-label, non-inferiority, randomised phase III: SOFT study
      Hideo Baba, Yasuhide Yamada, Daisuke Takahari, Hiroshi Matsumoto, Kazuhiro Yoshida, Masato Nakamura, Motoki Yoshida, Shigeyoshi Iwamoto, Ken Shimada, Yoshito Komatsu, Yasutsuna Sasaki, Taroh Satoh, Keiichi Takahashi, Hideyuki Mishima, Kei Muro, Masahiko Watanabe, Yuh Sakata, Satoshi Morita, Yasuhiro Shimada, Kenichi Sugihara
      ESMO Open Mar 2017, 2 (1) e000135; DOI: 10.1136/esmoopen-2016-000135

  6. Maurer, Christian

    1. Male breast cancer: finding the way in this uncommon path
      Christian Maurer, Samuel Martel, Evandro de Azambuja
      ESMO Open Mar 2017, 2 (1) e000169; DOI: 10.1136/esmoopen-2017-000169

  7. Mellemgaard, Anders

    1. Time since start of first-line therapy as a predictive clinical marker for nintedanib in patients with previously treated non-small cell lung cancer
      Birgit Gaschler-Markefski, Patricia Sikken, John V Heymach, Maya Gottfried, Anders Mellemgaard, Silvia Novello, Claudia-Nanette Gann, José Barrueco, Martin Reck, Nasser H Hanna, Rolf Kaiser
      ESMO Open Apr 2017, 2 (1) e000102; DOI: 10.1136/esmoopen-2016-000102

  8. Melotti, Barbara

    1. Impact of intervention aimed at improving the integration of oncology units and local palliative care services: results of the multicentre prospective sequential MIRTO study
      Andrea A Martoni, Barbara Melotti, Claudia Degli Esposti, Vita Mutri, Giorgio Lelli, Silvia Ansaloni, Erico Piva, Elena Strocchi, Franco Pannuti
      ESMO Open Mar 2017, 2 (1) e000116; DOI: 10.1136/esmoopen-2016-000116

  9. Migali, Cristina

    1. Indolent peritoneal mesothelioma: PI3K-mTOR inhibitors as a novel therapeutic strategy
      Saoirse O Dolly, Cristina Migali, Nina Tunariu, Chiara Della-Pepa, Shelize Khakoo, Steve Hazell, Johann S de Bono, Stanley B Kaye, Susana Banerjee
      ESMO Open Apr 2017, 2 (1) e000101; DOI: 10.1136/esmoopen-2016-000101

  10. Miki, Akira

    1. Phase I study of neoadjuvant chemotherapy with S-1 and oxaliplatin for locally advanced gastric cancer (Neo G-SOX PI)
      Hironaga Satake, Akira Miki, Masato Kondo, Takeshi Kotake, Yoshihiro Okita, Yukimasa Hatachi, Hisateru Yasui, Yukihiro Imai, Chihiro Ichikawa, Kenta Murotani, Hiroki Hashida, Hiroyuki Kobayashi, Masahito Kotaka, Takeshi Kato, Satoshi Kaihara, Akihito Tsuji
      ESMO Open Mar 2017, 2 (1) e000130; DOI: 10.1136/esmoopen-2016-000130

  11. Mishima, Hideyuki

    1. S-1 and oxaliplatin (SOX) plus bevacizumab versus mFOLFOX6 plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer: updated overall survival analyses of the open-label, non-inferiority, randomised phase III: SOFT study
      Hideo Baba, Yasuhide Yamada, Daisuke Takahari, Hiroshi Matsumoto, Kazuhiro Yoshida, Masato Nakamura, Motoki Yoshida, Shigeyoshi Iwamoto, Ken Shimada, Yoshito Komatsu, Yasutsuna Sasaki, Taroh Satoh, Keiichi Takahashi, Hideyuki Mishima, Kei Muro, Masahiko Watanabe, Yuh Sakata, Satoshi Morita, Yasuhiro Shimada, Kenichi Sugihara
      ESMO Open Mar 2017, 2 (1) e000135; DOI: 10.1136/esmoopen-2016-000135

  12. Mizumoto, Kazuhiro

    1. Health-related quality of life in a randomised phase III study of gemcitabine plus S-1, S-1 alone and gemcitabine alone for locally advanced or metastatic pancreatic cancer: GEST study
      Yasuhiro Hagiwara, Yasuo Ohashi, Takuji Okusaka, Hideki Ueno, Tatsuya Ioka, Narikazu Boku, Shinichi Egawa, Takashi Hatori, Junji Furuse, Kazuhiro Mizumoto, Shinichi Ohkawa, Taketo Yamaguchi, Kenji Yamao, Akihiro Funakoshi, Ann-Lii Cheng, Kiyohiro Kihara, Atsushi Sato, Masao Tanaka
      ESMO Open Mar 2017, 2 (1) e000151; DOI: 10.1136/esmoopen-2016-000151

  13. More, Sucheta

    1. Phase III study of gefitinib or pemetrexed with carboplatin in EGFR-mutated advanced lung adenocarcinoma
      Vijay Maruti Patil, Vanita Noronha, Amit Joshi, Anuradha Bharat Choughule, Atanu Bhattacharjee, Rajiv Kumar, Supriya Goud, Sucheta More, Anant Ramaswamy, Ashay Karpe, Nikhil Pande, Arun Chandrasekharan, Alok Goel, Vikas Talreja, Abhishek Mahajan, Amit Janu, Nilendu Purandare, Kumar Prabhash
      ESMO Open Apr 2017, 2 (1) e000168; DOI: 10.1136/esmoopen-2017-000168

  14. Morita, Satoshi

    1. S-1 and oxaliplatin (SOX) plus bevacizumab versus mFOLFOX6 plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer: updated overall survival analyses of the open-label, non-inferiority, randomised phase III: SOFT study
      Hideo Baba, Yasuhide Yamada, Daisuke Takahari, Hiroshi Matsumoto, Kazuhiro Yoshida, Masato Nakamura, Motoki Yoshida, Shigeyoshi Iwamoto, Ken Shimada, Yoshito Komatsu, Yasutsuna Sasaki, Taroh Satoh, Keiichi Takahashi, Hideyuki Mishima, Kei Muro, Masahiko Watanabe, Yuh Sakata, Satoshi Morita, Yasuhiro Shimada, Kenichi Sugihara
      ESMO Open Mar 2017, 2 (1) e000135; DOI: 10.1136/esmoopen-2016-000135

  15. Muro, Kei

    1. S-1 and oxaliplatin (SOX) plus bevacizumab versus mFOLFOX6 plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer: updated overall survival analyses of the open-label, non-inferiority, randomised phase III: SOFT study
      Hideo Baba, Yasuhide Yamada, Daisuke Takahari, Hiroshi Matsumoto, Kazuhiro Yoshida, Masato Nakamura, Motoki Yoshida, Shigeyoshi Iwamoto, Ken Shimada, Yoshito Komatsu, Yasutsuna Sasaki, Taroh Satoh, Keiichi Takahashi, Hideyuki Mishima, Kei Muro, Masahiko Watanabe, Yuh Sakata, Satoshi Morita, Yasuhiro Shimada, Kenichi Sugihara
      ESMO Open Mar 2017, 2 (1) e000135; DOI: 10.1136/esmoopen-2016-000135

  16. Murotani, Kenta

    1. Phase I study of neoadjuvant chemotherapy with S-1 and oxaliplatin for locally advanced gastric cancer (Neo G-SOX PI)
      Hironaga Satake, Akira Miki, Masato Kondo, Takeshi Kotake, Yoshihiro Okita, Yukimasa Hatachi, Hisateru Yasui, Yukihiro Imai, Chihiro Ichikawa, Kenta Murotani, Hiroki Hashida, Hiroyuki Kobayashi, Masahito Kotaka, Takeshi Kato, Satoshi Kaihara, Akihito Tsuji
      ESMO Open Mar 2017, 2 (1) e000130; DOI: 10.1136/esmoopen-2016-000130

  17. Mutri, Vita

    1. Impact of intervention aimed at improving the integration of oncology units and local palliative care services: results of the multicentre prospective sequential MIRTO study
      Andrea A Martoni, Barbara Melotti, Claudia Degli Esposti, Vita Mutri, Giorgio Lelli, Silvia Ansaloni, Erico Piva, Elena Strocchi, Franco Pannuti
      ESMO Open Mar 2017, 2 (1) e000116; DOI: 10.1136/esmoopen-2016-000116

N

  1. Nakagawa, Kazuhiko

    1. Peritumoural ground-glass opacity associated with tumour pseudoprogression in a patient with non-small cell lung cancer treated with nivolumab
      Ryoji Kato, Hidetoshi Hayashi, Junko Tanizaki, Kaoru Tanaka, Masayuki Takeda, Kazuhiko Nakagawa
      ESMO Open Mar 2017, 2 (1) e000145; DOI: 10.1136/esmoopen-2016-000145

  2. Nakamura, Masato

    1. S-1 and oxaliplatin (SOX) plus bevacizumab versus mFOLFOX6 plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer: updated overall survival analyses of the open-label, non-inferiority, randomised phase III: SOFT study
      Hideo Baba, Yasuhide Yamada, Daisuke Takahari, Hiroshi Matsumoto, Kazuhiro Yoshida, Masato Nakamura, Motoki Yoshida, Shigeyoshi Iwamoto, Ken Shimada, Yoshito Komatsu, Yasutsuna Sasaki, Taroh Satoh, Keiichi Takahashi, Hideyuki Mishima, Kei Muro, Masahiko Watanabe, Yuh Sakata, Satoshi Morita, Yasuhiro Shimada, Kenichi Sugihara
      ESMO Open Mar 2017, 2 (1) e000135; DOI: 10.1136/esmoopen-2016-000135

  3. Narukami, Ryo

    1. Prevalence of hypothyroidism among patients with breast cancer treated with radiation to the supraclavicular field: a single-centre survey
      Yuichiro Kikawa, Yasuhiro Kosaka, Kazuki Hashimoto, Eri Hohokabe, Sayaka Takebe, Ryo Narukami, Takayuki Hattori, Kazuhiro Ueki, Kengo Ogura, Toshiyuki Imagumbai, Hironori Kato, Masaki Kokubo
      ESMO Open Apr 2017, 2 (1) e000161; DOI: 10.1136/esmoopen-2017-000161

  4. Normanno, Nicola

    1. Management of metastatic colorectal cancer patients: guidelines of the Italian Medical Oncology Association (AIOM)
      Lisa Salvatore, Giuseppe Aprile, Ermenegildo Arnoldi, Carlo Aschele, Carlo Carnaghi, Maurizio Cosimelli, Evaristo Maiello, Nicola Normanno, Stefania Sciallero, Francesca Valvo, Giordano D Beretta
      ESMO Open Apr 2017, 2 (1) e000147; DOI: 10.1136/esmoopen-2016-000147

  5. Noronha, Vanita

    1. Phase III study of gefitinib or pemetrexed with carboplatin in EGFR-mutated advanced lung adenocarcinoma
      Vijay Maruti Patil, Vanita Noronha, Amit Joshi, Anuradha Bharat Choughule, Atanu Bhattacharjee, Rajiv Kumar, Supriya Goud, Sucheta More, Anant Ramaswamy, Ashay Karpe, Nikhil Pande, Arun Chandrasekharan, Alok Goel, Vikas Talreja, Abhishek Mahajan, Amit Janu, Nilendu Purandare, Kumar Prabhash
      ESMO Open Apr 2017, 2 (1) e000168; DOI: 10.1136/esmoopen-2017-000168

  6. Novello, Silvia

    1. Pemetrexed-cisplatin with concurrent thoracic radiation after pemetrexed-cisplatin induction in patients with unresectable locally advanced non-squamous NSCLC: results by age subgroup
      Pilar Garrido, Nadia Chouaki, Monika Serke, Philippe Giraud, Umberto Ricardi, Carmen Vallejo, Carla Visseren-Grul, Victoria Soldatenkova, Silvia Novello
      ESMO Open Mar 2017, 2 (1) e000141; DOI: 10.1136/esmoopen-2016-000141
    2. Time since start of first-line therapy as a predictive clinical marker for nintedanib in patients with previously treated non-small cell lung cancer
      Birgit Gaschler-Markefski, Patricia Sikken, John V Heymach, Maya Gottfried, Anders Mellemgaard, Silvia Novello, Claudia-Nanette Gann, José Barrueco, Martin Reck, Nasser H Hanna, Rolf Kaiser
      ESMO Open Apr 2017, 2 (1) e000102; DOI: 10.1136/esmoopen-2016-000102

O

  1. Ogura, Kengo

    1. Prevalence of hypothyroidism among patients with breast cancer treated with radiation to the supraclavicular field: a single-centre survey
      Yuichiro Kikawa, Yasuhiro Kosaka, Kazuki Hashimoto, Eri Hohokabe, Sayaka Takebe, Ryo Narukami, Takayuki Hattori, Kazuhiro Ueki, Kengo Ogura, Toshiyuki Imagumbai, Hironori Kato, Masaki Kokubo
      ESMO Open Apr 2017, 2 (1) e000161; DOI: 10.1136/esmoopen-2017-000161

  2. Ohashi, Yasuo

    1. Health-related quality of life in a randomised phase III study of gemcitabine plus S-1, S-1 alone and gemcitabine alone for locally advanced or metastatic pancreatic cancer: GEST study
      Yasuhiro Hagiwara, Yasuo Ohashi, Takuji Okusaka, Hideki Ueno, Tatsuya Ioka, Narikazu Boku, Shinichi Egawa, Takashi Hatori, Junji Furuse, Kazuhiro Mizumoto, Shinichi Ohkawa, Taketo Yamaguchi, Kenji Yamao, Akihiro Funakoshi, Ann-Lii Cheng, Kiyohiro Kihara, Atsushi Sato, Masao Tanaka
      ESMO Open Mar 2017, 2 (1) e000151; DOI: 10.1136/esmoopen-2016-000151

  3. Ohkawa, Shinichi

    1. Health-related quality of life in a randomised phase III study of gemcitabine plus S-1, S-1 alone and gemcitabine alone for locally advanced or metastatic pancreatic cancer: GEST study
      Yasuhiro Hagiwara, Yasuo Ohashi, Takuji Okusaka, Hideki Ueno, Tatsuya Ioka, Narikazu Boku, Shinichi Egawa, Takashi Hatori, Junji Furuse, Kazuhiro Mizumoto, Shinichi Ohkawa, Taketo Yamaguchi, Kenji Yamao, Akihiro Funakoshi, Ann-Lii Cheng, Kiyohiro Kihara, Atsushi Sato, Masao Tanaka
      ESMO Open Mar 2017, 2 (1) e000151; DOI: 10.1136/esmoopen-2016-000151

  4. Okita, Yoshihiro

    1. Phase I study of neoadjuvant chemotherapy with S-1 and oxaliplatin for locally advanced gastric cancer (Neo G-SOX PI)
      Hironaga Satake, Akira Miki, Masato Kondo, Takeshi Kotake, Yoshihiro Okita, Yukimasa Hatachi, Hisateru Yasui, Yukihiro Imai, Chihiro Ichikawa, Kenta Murotani, Hiroki Hashida, Hiroyuki Kobayashi, Masahito Kotaka, Takeshi Kato, Satoshi Kaihara, Akihito Tsuji
      ESMO Open Mar 2017, 2 (1) e000130; DOI: 10.1136/esmoopen-2016-000130

  5. Okusaka, Takuji

    1. Health-related quality of life in a randomised phase III study of gemcitabine plus S-1, S-1 alone and gemcitabine alone for locally advanced or metastatic pancreatic cancer: GEST study
      Yasuhiro Hagiwara, Yasuo Ohashi, Takuji Okusaka, Hideki Ueno, Tatsuya Ioka, Narikazu Boku, Shinichi Egawa, Takashi Hatori, Junji Furuse, Kazuhiro Mizumoto, Shinichi Ohkawa, Taketo Yamaguchi, Kenji Yamao, Akihiro Funakoshi, Ann-Lii Cheng, Kiyohiro Kihara, Atsushi Sato, Masao Tanaka
      ESMO Open Mar 2017, 2 (1) e000151; DOI: 10.1136/esmoopen-2016-000151

P

  1. Pande, Nikhil

    1. Phase III study of gefitinib or pemetrexed with carboplatin in EGFR-mutated advanced lung adenocarcinoma
      Vijay Maruti Patil, Vanita Noronha, Amit Joshi, Anuradha Bharat Choughule, Atanu Bhattacharjee, Rajiv Kumar, Supriya Goud, Sucheta More, Anant Ramaswamy, Ashay Karpe, Nikhil Pande, Arun Chandrasekharan, Alok Goel, Vikas Talreja, Abhishek Mahajan, Amit Janu, Nilendu Purandare, Kumar Prabhash
      ESMO Open Apr 2017, 2 (1) e000168; DOI: 10.1136/esmoopen-2017-000168

  2. Pannuti, Franco

    1. Impact of intervention aimed at improving the integration of oncology units and local palliative care services: results of the multicentre prospective sequential MIRTO study
      Andrea A Martoni, Barbara Melotti, Claudia Degli Esposti, Vita Mutri, Giorgio Lelli, Silvia Ansaloni, Erico Piva, Elena Strocchi, Franco Pannuti
      ESMO Open Mar 2017, 2 (1) e000116; DOI: 10.1136/esmoopen-2016-000116

  3. Passiglia, Francesco

    1. Immune checkpoint inhibitors in lung cancer: the holy grail has not yet been found…
      Satheesh Thungappa, Jose Ferri, Christian Caglevic, Francesco Passiglia, Luis Raez, Christian Rolfo
      ESMO Open Mar 2017, 2 (1) e000162; DOI: 10.1136/esmoopen-2017-000162

  4. Patil, Vijay Maruti

    1. Phase III study of gefitinib or pemetrexed with carboplatin in EGFR-mutated advanced lung adenocarcinoma
      Vijay Maruti Patil, Vanita Noronha, Amit Joshi, Anuradha Bharat Choughule, Atanu Bhattacharjee, Rajiv Kumar, Supriya Goud, Sucheta More, Anant Ramaswamy, Ashay Karpe, Nikhil Pande, Arun Chandrasekharan, Alok Goel, Vikas Talreja, Abhishek Mahajan, Amit Janu, Nilendu Purandare, Kumar Prabhash
      ESMO Open Apr 2017, 2 (1) e000168; DOI: 10.1136/esmoopen-2017-000168

  5. Piva, Erico

    1. Impact of intervention aimed at improving the integration of oncology units and local palliative care services: results of the multicentre prospective sequential MIRTO study
      Andrea A Martoni, Barbara Melotti, Claudia Degli Esposti, Vita Mutri, Giorgio Lelli, Silvia Ansaloni, Erico Piva, Elena Strocchi, Franco Pannuti
      ESMO Open Mar 2017, 2 (1) e000116; DOI: 10.1136/esmoopen-2016-000116

  6. Prabhash, Kumar

    1. Phase III study of gefitinib or pemetrexed with carboplatin in EGFR-mutated advanced lung adenocarcinoma
      Vijay Maruti Patil, Vanita Noronha, Amit Joshi, Anuradha Bharat Choughule, Atanu Bhattacharjee, Rajiv Kumar, Supriya Goud, Sucheta More, Anant Ramaswamy, Ashay Karpe, Nikhil Pande, Arun Chandrasekharan, Alok Goel, Vikas Talreja, Abhishek Mahajan, Amit Janu, Nilendu Purandare, Kumar Prabhash
      ESMO Open Apr 2017, 2 (1) e000168; DOI: 10.1136/esmoopen-2017-000168

  7. Purandare, Nilendu

    1. Phase III study of gefitinib or pemetrexed with carboplatin in EGFR-mutated advanced lung adenocarcinoma
      Vijay Maruti Patil, Vanita Noronha, Amit Joshi, Anuradha Bharat Choughule, Atanu Bhattacharjee, Rajiv Kumar, Supriya Goud, Sucheta More, Anant Ramaswamy, Ashay Karpe, Nikhil Pande, Arun Chandrasekharan, Alok Goel, Vikas Talreja, Abhishek Mahajan, Amit Janu, Nilendu Purandare, Kumar Prabhash
      ESMO Open Apr 2017, 2 (1) e000168; DOI: 10.1136/esmoopen-2017-000168

R

  1. Raez, Luis

    1. Immune checkpoint inhibitors in lung cancer: the holy grail has not yet been found…
      Satheesh Thungappa, Jose Ferri, Christian Caglevic, Francesco Passiglia, Luis Raez, Christian Rolfo
      ESMO Open Mar 2017, 2 (1) e000162; DOI: 10.1136/esmoopen-2017-000162

  2. Ramaswamy, Anant

    1. Phase III study of gefitinib or pemetrexed with carboplatin in EGFR-mutated advanced lung adenocarcinoma
      Vijay Maruti Patil, Vanita Noronha, Amit Joshi, Anuradha Bharat Choughule, Atanu Bhattacharjee, Rajiv Kumar, Supriya Goud, Sucheta More, Anant Ramaswamy, Ashay Karpe, Nikhil Pande, Arun Chandrasekharan, Alok Goel, Vikas Talreja, Abhishek Mahajan, Amit Janu, Nilendu Purandare, Kumar Prabhash
      ESMO Open Apr 2017, 2 (1) e000168; DOI: 10.1136/esmoopen-2017-000168

  3. Reck, Martin

    1. Time since start of first-line therapy as a predictive clinical marker for nintedanib in patients with previously treated non-small cell lung cancer
      Birgit Gaschler-Markefski, Patricia Sikken, John V Heymach, Maya Gottfried, Anders Mellemgaard, Silvia Novello, Claudia-Nanette Gann, José Barrueco, Martin Reck, Nasser H Hanna, Rolf Kaiser
      ESMO Open Apr 2017, 2 (1) e000102; DOI: 10.1136/esmoopen-2016-000102

  4. Ricardi, Umberto

    1. Pemetrexed-cisplatin with concurrent thoracic radiation after pemetrexed-cisplatin induction in patients with unresectable locally advanced non-squamous NSCLC: results by age subgroup
      Pilar Garrido, Nadia Chouaki, Monika Serke, Philippe Giraud, Umberto Ricardi, Carmen Vallejo, Carla Visseren-Grul, Victoria Soldatenkova, Silvia Novello
      ESMO Open Mar 2017, 2 (1) e000141; DOI: 10.1136/esmoopen-2016-000141

  5. Rolfo, Christian

    1. Immune checkpoint inhibitors in lung cancer: the holy grail has not yet been found…
      Satheesh Thungappa, Jose Ferri, Christian Caglevic, Francesco Passiglia, Luis Raez, Christian Rolfo
      ESMO Open Mar 2017, 2 (1) e000162; DOI: 10.1136/esmoopen-2017-000162

S

  1. Sakata, Yuh

    1. S-1 and oxaliplatin (SOX) plus bevacizumab versus mFOLFOX6 plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer: updated overall survival analyses of the open-label, non-inferiority, randomised phase III: SOFT study
      Hideo Baba, Yasuhide Yamada, Daisuke Takahari, Hiroshi Matsumoto, Kazuhiro Yoshida, Masato Nakamura, Motoki Yoshida, Shigeyoshi Iwamoto, Ken Shimada, Yoshito Komatsu, Yasutsuna Sasaki, Taroh Satoh, Keiichi Takahashi, Hideyuki Mishima, Kei Muro, Masahiko Watanabe, Yuh Sakata, Satoshi Morita, Yasuhiro Shimada, Kenichi Sugihara
      ESMO Open Mar 2017, 2 (1) e000135; DOI: 10.1136/esmoopen-2016-000135

  2. Salvatore, Lisa

    1. Management of metastatic colorectal cancer patients: guidelines of the Italian Medical Oncology Association (AIOM)
      Lisa Salvatore, Giuseppe Aprile, Ermenegildo Arnoldi, Carlo Aschele, Carlo Carnaghi, Maurizio Cosimelli, Evaristo Maiello, Nicola Normanno, Stefania Sciallero, Francesca Valvo, Giordano D Beretta
      ESMO Open Apr 2017, 2 (1) e000147; DOI: 10.1136/esmoopen-2016-000147

  3. Sasaki, Yasutsuna

    1. S-1 and oxaliplatin (SOX) plus bevacizumab versus mFOLFOX6 plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer: updated overall survival analyses of the open-label, non-inferiority, randomised phase III: SOFT study
      Hideo Baba, Yasuhide Yamada, Daisuke Takahari, Hiroshi Matsumoto, Kazuhiro Yoshida, Masato Nakamura, Motoki Yoshida, Shigeyoshi Iwamoto, Ken Shimada, Yoshito Komatsu, Yasutsuna Sasaki, Taroh Satoh, Keiichi Takahashi, Hideyuki Mishima, Kei Muro, Masahiko Watanabe, Yuh Sakata, Satoshi Morita, Yasuhiro Shimada, Kenichi Sugihara
      ESMO Open Mar 2017, 2 (1) e000135; DOI: 10.1136/esmoopen-2016-000135

  4. Satake, Hironaga

    1. Phase I study of neoadjuvant chemotherapy with S-1 and oxaliplatin for locally advanced gastric cancer (Neo G-SOX PI)
      Hironaga Satake, Akira Miki, Masato Kondo, Takeshi Kotake, Yoshihiro Okita, Yukimasa Hatachi, Hisateru Yasui, Yukihiro Imai, Chihiro Ichikawa, Kenta Murotani, Hiroki Hashida, Hiroyuki Kobayashi, Masahito Kotaka, Takeshi Kato, Satoshi Kaihara, Akihito Tsuji
      ESMO Open Mar 2017, 2 (1) e000130; DOI: 10.1136/esmoopen-2016-000130

  5. Sato, Atsushi

    1. Health-related quality of life in a randomised phase III study of gemcitabine plus S-1, S-1 alone and gemcitabine alone for locally advanced or metastatic pancreatic cancer: GEST study
      Yasuhiro Hagiwara, Yasuo Ohashi, Takuji Okusaka, Hideki Ueno, Tatsuya Ioka, Narikazu Boku, Shinichi Egawa, Takashi Hatori, Junji Furuse, Kazuhiro Mizumoto, Shinichi Ohkawa, Taketo Yamaguchi, Kenji Yamao, Akihiro Funakoshi, Ann-Lii Cheng, Kiyohiro Kihara, Atsushi Sato, Masao Tanaka
      ESMO Open Mar 2017, 2 (1) e000151; DOI: 10.1136/esmoopen-2016-000151

  6. Satoh, Taroh

    1. S-1 and oxaliplatin (SOX) plus bevacizumab versus mFOLFOX6 plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer: updated overall survival analyses of the open-label, non-inferiority, randomised phase III: SOFT study
      Hideo Baba, Yasuhide Yamada, Daisuke Takahari, Hiroshi Matsumoto, Kazuhiro Yoshida, Masato Nakamura, Motoki Yoshida, Shigeyoshi Iwamoto, Ken Shimada, Yoshito Komatsu, Yasutsuna Sasaki, Taroh Satoh, Keiichi Takahashi, Hideyuki Mishima, Kei Muro, Masahiko Watanabe, Yuh Sakata, Satoshi Morita, Yasuhiro Shimada, Kenichi Sugihara
      ESMO Open Mar 2017, 2 (1) e000135; DOI: 10.1136/esmoopen-2016-000135

  7. Sciallero, Stefania

    1. Management of metastatic colorectal cancer patients: guidelines of the Italian Medical Oncology Association (AIOM)
      Lisa Salvatore, Giuseppe Aprile, Ermenegildo Arnoldi, Carlo Aschele, Carlo Carnaghi, Maurizio Cosimelli, Evaristo Maiello, Nicola Normanno, Stefania Sciallero, Francesca Valvo, Giordano D Beretta
      ESMO Open Apr 2017, 2 (1) e000147; DOI: 10.1136/esmoopen-2016-000147

  8. Serke, Monika

    1. Pemetrexed-cisplatin with concurrent thoracic radiation after pemetrexed-cisplatin induction in patients with unresectable locally advanced non-squamous NSCLC: results by age subgroup
      Pilar Garrido, Nadia Chouaki, Monika Serke, Philippe Giraud, Umberto Ricardi, Carmen Vallejo, Carla Visseren-Grul, Victoria Soldatenkova, Silvia Novello
      ESMO Open Mar 2017, 2 (1) e000141; DOI: 10.1136/esmoopen-2016-000141

  9. Shimada, Ken

    1. S-1 and oxaliplatin (SOX) plus bevacizumab versus mFOLFOX6 plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer: updated overall survival analyses of the open-label, non-inferiority, randomised phase III: SOFT study
      Hideo Baba, Yasuhide Yamada, Daisuke Takahari, Hiroshi Matsumoto, Kazuhiro Yoshida, Masato Nakamura, Motoki Yoshida, Shigeyoshi Iwamoto, Ken Shimada, Yoshito Komatsu, Yasutsuna Sasaki, Taroh Satoh, Keiichi Takahashi, Hideyuki Mishima, Kei Muro, Masahiko Watanabe, Yuh Sakata, Satoshi Morita, Yasuhiro Shimada, Kenichi Sugihara
      ESMO Open Mar 2017, 2 (1) e000135; DOI: 10.1136/esmoopen-2016-000135

  10. Shimada, Yasuhiro

    1. S-1 and oxaliplatin (SOX) plus bevacizumab versus mFOLFOX6 plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer: updated overall survival analyses of the open-label, non-inferiority, randomised phase III: SOFT study
      Hideo Baba, Yasuhide Yamada, Daisuke Takahari, Hiroshi Matsumoto, Kazuhiro Yoshida, Masato Nakamura, Motoki Yoshida, Shigeyoshi Iwamoto, Ken Shimada, Yoshito Komatsu, Yasutsuna Sasaki, Taroh Satoh, Keiichi Takahashi, Hideyuki Mishima, Kei Muro, Masahiko Watanabe, Yuh Sakata, Satoshi Morita, Yasuhiro Shimada, Kenichi Sugihara
      ESMO Open Mar 2017, 2 (1) e000135; DOI: 10.1136/esmoopen-2016-000135

  11. Sikken, Patricia

    1. Time since start of first-line therapy as a predictive clinical marker for nintedanib in patients with previously treated non-small cell lung cancer
      Birgit Gaschler-Markefski, Patricia Sikken, John V Heymach, Maya Gottfried, Anders Mellemgaard, Silvia Novello, Claudia-Nanette Gann, José Barrueco, Martin Reck, Nasser H Hanna, Rolf Kaiser
      ESMO Open Apr 2017, 2 (1) e000102; DOI: 10.1136/esmoopen-2016-000102

  12. Sobrero, Alberto

    1. The hard road to ranking the clinical benefit of antineoplastic agents: ESMO Award 2016 presentation
      Alberto Sobrero
      ESMO Open Mar 2017, 2 (1) e000157; DOI: 10.1136/esmoopen-2017-000157

  13. Soldatenkova, Victoria

    1. Pemetrexed-cisplatin with concurrent thoracic radiation after pemetrexed-cisplatin induction in patients with unresectable locally advanced non-squamous NSCLC: results by age subgroup
      Pilar Garrido, Nadia Chouaki, Monika Serke, Philippe Giraud, Umberto Ricardi, Carmen Vallejo, Carla Visseren-Grul, Victoria Soldatenkova, Silvia Novello
      ESMO Open Mar 2017, 2 (1) e000141; DOI: 10.1136/esmoopen-2016-000141

  14. Strocchi, Elena

    1. Impact of intervention aimed at improving the integration of oncology units and local palliative care services: results of the multicentre prospective sequential MIRTO study
      Andrea A Martoni, Barbara Melotti, Claudia Degli Esposti, Vita Mutri, Giorgio Lelli, Silvia Ansaloni, Erico Piva, Elena Strocchi, Franco Pannuti
      ESMO Open Mar 2017, 2 (1) e000116; DOI: 10.1136/esmoopen-2016-000116

  15. Sugihara, Kenichi

    1. S-1 and oxaliplatin (SOX) plus bevacizumab versus mFOLFOX6 plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer: updated overall survival analyses of the open-label, non-inferiority, randomised phase III: SOFT study
      Hideo Baba, Yasuhide Yamada, Daisuke Takahari, Hiroshi Matsumoto, Kazuhiro Yoshida, Masato Nakamura, Motoki Yoshida, Shigeyoshi Iwamoto, Ken Shimada, Yoshito Komatsu, Yasutsuna Sasaki, Taroh Satoh, Keiichi Takahashi, Hideyuki Mishima, Kei Muro, Masahiko Watanabe, Yuh Sakata, Satoshi Morita, Yasuhiro Shimada, Kenichi Sugihara
      ESMO Open Mar 2017, 2 (1) e000135; DOI: 10.1136/esmoopen-2016-000135

T

  1. Takahari, Daisuke

    1. S-1 and oxaliplatin (SOX) plus bevacizumab versus mFOLFOX6 plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer: updated overall survival analyses of the open-label, non-inferiority, randomised phase III: SOFT study
      Hideo Baba, Yasuhide Yamada, Daisuke Takahari, Hiroshi Matsumoto, Kazuhiro Yoshida, Masato Nakamura, Motoki Yoshida, Shigeyoshi Iwamoto, Ken Shimada, Yoshito Komatsu, Yasutsuna Sasaki, Taroh Satoh, Keiichi Takahashi, Hideyuki Mishima, Kei Muro, Masahiko Watanabe, Yuh Sakata, Satoshi Morita, Yasuhiro Shimada, Kenichi Sugihara
      ESMO Open Mar 2017, 2 (1) e000135; DOI: 10.1136/esmoopen-2016-000135

  2. Takahashi, Keiichi

    1. S-1 and oxaliplatin (SOX) plus bevacizumab versus mFOLFOX6 plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer: updated overall survival analyses of the open-label, non-inferiority, randomised phase III: SOFT study
      Hideo Baba, Yasuhide Yamada, Daisuke Takahari, Hiroshi Matsumoto, Kazuhiro Yoshida, Masato Nakamura, Motoki Yoshida, Shigeyoshi Iwamoto, Ken Shimada, Yoshito Komatsu, Yasutsuna Sasaki, Taroh Satoh, Keiichi Takahashi, Hideyuki Mishima, Kei Muro, Masahiko Watanabe, Yuh Sakata, Satoshi Morita, Yasuhiro Shimada, Kenichi Sugihara
      ESMO Open Mar 2017, 2 (1) e000135; DOI: 10.1136/esmoopen-2016-000135

  3. Takebe, Sayaka

    1. Prevalence of hypothyroidism among patients with breast cancer treated with radiation to the supraclavicular field: a single-centre survey
      Yuichiro Kikawa, Yasuhiro Kosaka, Kazuki Hashimoto, Eri Hohokabe, Sayaka Takebe, Ryo Narukami, Takayuki Hattori, Kazuhiro Ueki, Kengo Ogura, Toshiyuki Imagumbai, Hironori Kato, Masaki Kokubo
      ESMO Open Apr 2017, 2 (1) e000161; DOI: 10.1136/esmoopen-2017-000161

  4. Takeda, Masayuki

    1. Peritumoural ground-glass opacity associated with tumour pseudoprogression in a patient with non-small cell lung cancer treated with nivolumab
      Ryoji Kato, Hidetoshi Hayashi, Junko Tanizaki, Kaoru Tanaka, Masayuki Takeda, Kazuhiko Nakagawa
      ESMO Open Mar 2017, 2 (1) e000145; DOI: 10.1136/esmoopen-2016-000145

  5. Talreja, Vikas

    1. Phase III study of gefitinib or pemetrexed with carboplatin in EGFR-mutated advanced lung adenocarcinoma
      Vijay Maruti Patil, Vanita Noronha, Amit Joshi, Anuradha Bharat Choughule, Atanu Bhattacharjee, Rajiv Kumar, Supriya Goud, Sucheta More, Anant Ramaswamy, Ashay Karpe, Nikhil Pande, Arun Chandrasekharan, Alok Goel, Vikas Talreja, Abhishek Mahajan, Amit Janu, Nilendu Purandare, Kumar Prabhash
      ESMO Open Apr 2017, 2 (1) e000168; DOI: 10.1136/esmoopen-2017-000168

  6. Tanaka, Kaoru

    1. Peritumoural ground-glass opacity associated with tumour pseudoprogression in a patient with non-small cell lung cancer treated with nivolumab
      Ryoji Kato, Hidetoshi Hayashi, Junko Tanizaki, Kaoru Tanaka, Masayuki Takeda, Kazuhiko Nakagawa
      ESMO Open Mar 2017, 2 (1) e000145; DOI: 10.1136/esmoopen-2016-000145

  7. Tanaka, Masao

    1. Health-related quality of life in a randomised phase III study of gemcitabine plus S-1, S-1 alone and gemcitabine alone for locally advanced or metastatic pancreatic cancer: GEST study
      Yasuhiro Hagiwara, Yasuo Ohashi, Takuji Okusaka, Hideki Ueno, Tatsuya Ioka, Narikazu Boku, Shinichi Egawa, Takashi Hatori, Junji Furuse, Kazuhiro Mizumoto, Shinichi Ohkawa, Taketo Yamaguchi, Kenji Yamao, Akihiro Funakoshi, Ann-Lii Cheng, Kiyohiro Kihara, Atsushi Sato, Masao Tanaka
      ESMO Open Mar 2017, 2 (1) e000151; DOI: 10.1136/esmoopen-2016-000151

  8. Tanizaki, Junko

    1. Peritumoural ground-glass opacity associated with tumour pseudoprogression in a patient with non-small cell lung cancer treated with nivolumab
      Ryoji Kato, Hidetoshi Hayashi, Junko Tanizaki, Kaoru Tanaka, Masayuki Takeda, Kazuhiko Nakagawa
      ESMO Open Mar 2017, 2 (1) e000145; DOI: 10.1136/esmoopen-2016-000145

  9. Terol, María José

    1. In the literature: February 2017
      Andrés Cervantes, María José Terol
      ESMO Open Mar 2017, 2 (1) e000171; DOI: 10.1136/esmoopen-2017-000171

  10. Thungappa, Satheesh

    1. Immune checkpoint inhibitors in lung cancer: the holy grail has not yet been found…
      Satheesh Thungappa, Jose Ferri, Christian Caglevic, Francesco Passiglia, Luis Raez, Christian Rolfo
      ESMO Open Mar 2017, 2 (1) e000162; DOI: 10.1136/esmoopen-2017-000162

  11. Tsuji, Akihito

    1. Phase I study of neoadjuvant chemotherapy with S-1 and oxaliplatin for locally advanced gastric cancer (Neo G-SOX PI)
      Hironaga Satake, Akira Miki, Masato Kondo, Takeshi Kotake, Yoshihiro Okita, Yukimasa Hatachi, Hisateru Yasui, Yukihiro Imai, Chihiro Ichikawa, Kenta Murotani, Hiroki Hashida, Hiroyuki Kobayashi, Masahito Kotaka, Takeshi Kato, Satoshi Kaihara, Akihito Tsuji
      ESMO Open Mar 2017, 2 (1) e000130; DOI: 10.1136/esmoopen-2016-000130

  12. Tunariu, Nina

    1. Indolent peritoneal mesothelioma: PI3K-mTOR inhibitors as a novel therapeutic strategy
      Saoirse O Dolly, Cristina Migali, Nina Tunariu, Chiara Della-Pepa, Shelize Khakoo, Steve Hazell, Johann S de Bono, Stanley B Kaye, Susana Banerjee
      ESMO Open Apr 2017, 2 (1) e000101; DOI: 10.1136/esmoopen-2016-000101

U

  1. Ueki, Kazuhiro

    1. Prevalence of hypothyroidism among patients with breast cancer treated with radiation to the supraclavicular field: a single-centre survey
      Yuichiro Kikawa, Yasuhiro Kosaka, Kazuki Hashimoto, Eri Hohokabe, Sayaka Takebe, Ryo Narukami, Takayuki Hattori, Kazuhiro Ueki, Kengo Ogura, Toshiyuki Imagumbai, Hironori Kato, Masaki Kokubo
      ESMO Open Apr 2017, 2 (1) e000161; DOI: 10.1136/esmoopen-2017-000161

  2. Ueno, Hideki

    1. Health-related quality of life in a randomised phase III study of gemcitabine plus S-1, S-1 alone and gemcitabine alone for locally advanced or metastatic pancreatic cancer: GEST study
      Yasuhiro Hagiwara, Yasuo Ohashi, Takuji Okusaka, Hideki Ueno, Tatsuya Ioka, Narikazu Boku, Shinichi Egawa, Takashi Hatori, Junji Furuse, Kazuhiro Mizumoto, Shinichi Ohkawa, Taketo Yamaguchi, Kenji Yamao, Akihiro Funakoshi, Ann-Lii Cheng, Kiyohiro Kihara, Atsushi Sato, Masao Tanaka
      ESMO Open Mar 2017, 2 (1) e000151; DOI: 10.1136/esmoopen-2016-000151

V

  1. Vallejo, Carmen

    1. Pemetrexed-cisplatin with concurrent thoracic radiation after pemetrexed-cisplatin induction in patients with unresectable locally advanced non-squamous NSCLC: results by age subgroup
      Pilar Garrido, Nadia Chouaki, Monika Serke, Philippe Giraud, Umberto Ricardi, Carmen Vallejo, Carla Visseren-Grul, Victoria Soldatenkova, Silvia Novello
      ESMO Open Mar 2017, 2 (1) e000141; DOI: 10.1136/esmoopen-2016-000141

  2. Valvo, Francesca

    1. Management of metastatic colorectal cancer patients: guidelines of the Italian Medical Oncology Association (AIOM)
      Lisa Salvatore, Giuseppe Aprile, Ermenegildo Arnoldi, Carlo Aschele, Carlo Carnaghi, Maurizio Cosimelli, Evaristo Maiello, Nicola Normanno, Stefania Sciallero, Francesca Valvo, Giordano D Beretta
      ESMO Open Apr 2017, 2 (1) e000147; DOI: 10.1136/esmoopen-2016-000147

  3. Visseren-Grul, Carla

    1. Pemetrexed-cisplatin with concurrent thoracic radiation after pemetrexed-cisplatin induction in patients with unresectable locally advanced non-squamous NSCLC: results by age subgroup
      Pilar Garrido, Nadia Chouaki, Monika Serke, Philippe Giraud, Umberto Ricardi, Carmen Vallejo, Carla Visseren-Grul, Victoria Soldatenkova, Silvia Novello
      ESMO Open Mar 2017, 2 (1) e000141; DOI: 10.1136/esmoopen-2016-000141

W

  1. Watanabe, Masahiko

    1. S-1 and oxaliplatin (SOX) plus bevacizumab versus mFOLFOX6 plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer: updated overall survival analyses of the open-label, non-inferiority, randomised phase III: SOFT study
      Hideo Baba, Yasuhide Yamada, Daisuke Takahari, Hiroshi Matsumoto, Kazuhiro Yoshida, Masato Nakamura, Motoki Yoshida, Shigeyoshi Iwamoto, Ken Shimada, Yoshito Komatsu, Yasutsuna Sasaki, Taroh Satoh, Keiichi Takahashi, Hideyuki Mishima, Kei Muro, Masahiko Watanabe, Yuh Sakata, Satoshi Morita, Yasuhiro Shimada, Kenichi Sugihara
      ESMO Open Mar 2017, 2 (1) e000135; DOI: 10.1136/esmoopen-2016-000135

Y

  1. Yamada, Yasuhide

    1. S-1 and oxaliplatin (SOX) plus bevacizumab versus mFOLFOX6 plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer: updated overall survival analyses of the open-label, non-inferiority, randomised phase III: SOFT study
      Hideo Baba, Yasuhide Yamada, Daisuke Takahari, Hiroshi Matsumoto, Kazuhiro Yoshida, Masato Nakamura, Motoki Yoshida, Shigeyoshi Iwamoto, Ken Shimada, Yoshito Komatsu, Yasutsuna Sasaki, Taroh Satoh, Keiichi Takahashi, Hideyuki Mishima, Kei Muro, Masahiko Watanabe, Yuh Sakata, Satoshi Morita, Yasuhiro Shimada, Kenichi Sugihara
      ESMO Open Mar 2017, 2 (1) e000135; DOI: 10.1136/esmoopen-2016-000135

  2. Yamaguchi, Taketo

    1. Health-related quality of life in a randomised phase III study of gemcitabine plus S-1, S-1 alone and gemcitabine alone for locally advanced or metastatic pancreatic cancer: GEST study
      Yasuhiro Hagiwara, Yasuo Ohashi, Takuji Okusaka, Hideki Ueno, Tatsuya Ioka, Narikazu Boku, Shinichi Egawa, Takashi Hatori, Junji Furuse, Kazuhiro Mizumoto, Shinichi Ohkawa, Taketo Yamaguchi, Kenji Yamao, Akihiro Funakoshi, Ann-Lii Cheng, Kiyohiro Kihara, Atsushi Sato, Masao Tanaka
      ESMO Open Mar 2017, 2 (1) e000151; DOI: 10.1136/esmoopen-2016-000151

  3. Yamao, Kenji

    1. Health-related quality of life in a randomised phase III study of gemcitabine plus S-1, S-1 alone and gemcitabine alone for locally advanced or metastatic pancreatic cancer: GEST study
      Yasuhiro Hagiwara, Yasuo Ohashi, Takuji Okusaka, Hideki Ueno, Tatsuya Ioka, Narikazu Boku, Shinichi Egawa, Takashi Hatori, Junji Furuse, Kazuhiro Mizumoto, Shinichi Ohkawa, Taketo Yamaguchi, Kenji Yamao, Akihiro Funakoshi, Ann-Lii Cheng, Kiyohiro Kihara, Atsushi Sato, Masao Tanaka
      ESMO Open Mar 2017, 2 (1) e000151; DOI: 10.1136/esmoopen-2016-000151

  4. Yasui, Hisateru

    1. Phase I study of neoadjuvant chemotherapy with S-1 and oxaliplatin for locally advanced gastric cancer (Neo G-SOX PI)
      Hironaga Satake, Akira Miki, Masato Kondo, Takeshi Kotake, Yoshihiro Okita, Yukimasa Hatachi, Hisateru Yasui, Yukihiro Imai, Chihiro Ichikawa, Kenta Murotani, Hiroki Hashida, Hiroyuki Kobayashi, Masahito Kotaka, Takeshi Kato, Satoshi Kaihara, Akihito Tsuji
      ESMO Open Mar 2017, 2 (1) e000130; DOI: 10.1136/esmoopen-2016-000130

  5. Yoshida, Kazuhiro

    1. S-1 and oxaliplatin (SOX) plus bevacizumab versus mFOLFOX6 plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer: updated overall survival analyses of the open-label, non-inferiority, randomised phase III: SOFT study
      Hideo Baba, Yasuhide Yamada, Daisuke Takahari, Hiroshi Matsumoto, Kazuhiro Yoshida, Masato Nakamura, Motoki Yoshida, Shigeyoshi Iwamoto, Ken Shimada, Yoshito Komatsu, Yasutsuna Sasaki, Taroh Satoh, Keiichi Takahashi, Hideyuki Mishima, Kei Muro, Masahiko Watanabe, Yuh Sakata, Satoshi Morita, Yasuhiro Shimada, Kenichi Sugihara
      ESMO Open Mar 2017, 2 (1) e000135; DOI: 10.1136/esmoopen-2016-000135

  6. Yoshida, Motoki

    1. S-1 and oxaliplatin (SOX) plus bevacizumab versus mFOLFOX6 plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer: updated overall survival analyses of the open-label, non-inferiority, randomised phase III: SOFT study
      Hideo Baba, Yasuhide Yamada, Daisuke Takahari, Hiroshi Matsumoto, Kazuhiro Yoshida, Masato Nakamura, Motoki Yoshida, Shigeyoshi Iwamoto, Ken Shimada, Yoshito Komatsu, Yasutsuna Sasaki, Taroh Satoh, Keiichi Takahashi, Hideyuki Mishima, Kei Muro, Masahiko Watanabe, Yuh Sakata, Satoshi Morita, Yasuhiro Shimada, Kenichi Sugihara
      ESMO Open Mar 2017, 2 (1) e000135; DOI: 10.1136/esmoopen-2016-000135